Onesource says Dr. Reddy's Semaglutide delay won't hit its ops
Clarification removes overhang but the company relies on qualitative reassurance without updated guidance.
— 1 earlier story on Onesource Specialty Pharma Ltd. →What's new
- Onesource clarified that Dr. Reddy's Semaglutide supply delay has no material impact on its own operations.
- The company cited sufficient demand from other customers, including Canada.
- Capacity additions remain on track starting this quarter.
Why this matters
The clarification removes a potential overhang from a key customer relationship, but the company offers only qualitative reassurance without quantified revenue impact or updated guidance. With trailing PAT down 95% and a thin ₹5 cr net profit in the latest quarter, the operational outlook remains uncertain.
What we're watching
- Revenue contribution from new capacity additions starting Q1 FY27.
- Whether Dr. Reddy's supply issues affect future order flow from Onesource.
- Next quarter's PAT trajectory after a dramatic collapse.
The full read
Onesource Specialty Pharma wants investors to know that Dr. Reddy's Semaglutide supply delay is not its problem. The ₹17,646 cr market-cap CDMO issued a clarification saying the delay has no material impact, backed by claims of sufficient demand from other customers, including Canada, and capacity additions starting this quarter. That removes a potential overhang from a key customer relationship. But the reassurance is qualitative. There is no quantified revenue exposure, no updated guidance. And the financial backdrop is fragile: trailing revenue growth is flat at 0.5%, PAT has collapsed 95%, and the latest quarter net profit was just ₹5 cr on sales of ₹428 cr. The clarification is constructive, but the real test is whether the new capacity actually translates into earnings.
Questions answered
- Why did Onesource issue this clarification?
- Dr. Reddy's disclosed a delay in Semaglutide commercial supplies, and Onesource moved to clarify that this does not materially affect its own operations.
- Does Onesource have other customers for Semaglutide?
- Yes, it has demand from other customers including Canada, and its existing capacities are fully committed. It is also adding new capacity this quarter.
- What was the company's latest financial performance?
- In the quarter ended March 2026, Onesource reported sales of ₹428 crore and net profit of ₹5 crore, with trailing PAT down 95% year-on-year.
- Is the Dr. Reddy's delay a risk for Onesource's growth?
- The company downplays the impact, but without quantified revenue exposure or updated guidance, the real risk remains unclear. The capacity expansion plans are still on track.
Onesource Specialty Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on ONESOURCE →- 9 Jul 2026 · 10:42 AM IST Onesource says Dr. Reddy's Semaglutide delay won't hit its ops
- 8d ago OneSource gets single FDA observation, PAT collapse looms larger